Ondansetron induced blindness: a pharmacovigilance database study

Barus, Romain; Potey, Camille; GAUTIER, Sophie; Wabont, Guillaume

Document type :

Article dans une revue scientifique: Article original

DOI :

10.1080/14740338.2023.2273334

PMID :

37852931

Permalink :

http://hdl.handle.net/20.500.12210/115409

Title :

Ondansetron induced blindness: a pharmacovigilance database study

Author(s) :

Barus, Romain [Auteur]
Service Pharmacologie Clinique [CHU Toulouse]
Potey, Camille [Auteur]
Département de Pharmacologie Médicale [Lille] [Pôle Recherche]
GAUTIER, Sophie [Auteur]
Département de Pharmacologie Médicale [Lille] [Pôle Recherche]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Wabont, Guillaume [Auteur]
Département de Pharmacologie Médicale [Lille] [Pôle Recherche]

Journal title :

Expert Opinion on Drug Safety

Abbreviated title :

Expert Opin Drug Saf

Volume number :

Pages :

1017-1020

Publisher :

Informa Healthcare

Publication date :

2023-10-24

ISSN :

1744-764X

English keyword(s) :

Adverse drug reaction
pharmacovigilance
VigiBase
ondansetron
blindness
drug safety

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background Ondansetron is an antiemetic drug (AED) used to prevent and treat nausea and vomiting. The summary of product characteristics reports a rare risk of transient blindness primarily during IV injections, notably ...
Show more >Background Ondansetron is an antiemetic drug (AED) used to prevent and treat nausea and vomiting. The summary of product characteristics reports a rare risk of transient blindness primarily during IV injections, notably with the concomitant use of chemotherapeutic agents. We aimed to refine the characterization of ondansetron-induced blindness. Research design and methods We performed a descriptive and a case/non-case analysis using VigiBase®. Cases were defined as reports of adverse drug reactions (ADRs) related to blindness: amaurosis, amaurosis fugax, blindness. Non-cases were all other recorded reactions. Reporting risk of blindness-related ADRs was assessed using a disproportionality analysis and expressed as Reporting Odds Ratios (ROR). Results 138,315 ADRs were reported with AEDs, including 136 blindness-related ADRs, among them 44 (32.4%) with ondansetron. For ondansetron users, blindness-related ADRs occurred mainly on the first day. Out of the 25 patients with known outcomes, 18 (72.0%) were recovering or had recovered, 7 (28.0%) patients had not recovered There were no statistical differences in the number of cases for IV or oral users and for users or not of chemotherapeutic agents. Compared with other AEDs, ondansetron was associated with an increase in the reporting risk of blindness-related ADRs (ROR = 4.00 [2.79–5.72], p < 0.001). Conclusions Rarely blindness can occur following intravenous or oral administration of ondansetron.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

Lille Neurosciences & Cognition (LilNCog) - U 1172

Submission date :

2024-06-22T21:38:10Z
2024-11-22T12:29:24Z

Version	Link	Modification date
2	20.500.12210/115409*	2024-11-22T12:18:40Z
1	20.500.12210/115409.1	2024-06-22T21:38:10Z

Ondansetron induced blindness: a ...

BibTeX

CSV

Excel

RIS

Version history

Ondansetron induced blindness: a ... BibTeX CSV Excel RIS

Version history

Ondansetron induced blindness: a ...

BibTeX

CSV

Excel

RIS